NYSE:BMYPharmaceuticals
Bristol-Myers Squibb (BMY) Is Up 6.8% After FDA Priority Review and Upgraded 2025 Guidance
In the past week, Bristol-Myers Squibb announced that the US FDA granted Priority Review to an sBLA for Breyanzi as a treatment for relapsed or refractory marginal zone lymphoma, with a decision expected by December 2025, and also raised its 2025 revenue guidance by US$700 million to US$46.5 billion–US$47.5 billion due to strong product performance and legacy sales.
This combination of regulatory progress and improved financial outlook signals renewed momentum in both the company’s...